Wave Bye is ending reactive period care.
Four billion women. Seven years of life spent bleeding. One new standard of care.
For over a century, period pain has been treated the same way: wait for it to start, then catch up. Wave Bye is building the first over-the-counter regimen taken before symptoms begin — cycle-timed, hormone-free, and grounded in the clinical literature.
This page is provided for informational purposes only. It is not an offer to sell, or a solicitation of an offer to buy, any security, and no securities are being offered. Nothing here constitutes investment, legal, tax, or medical advice. Any forward-looking statements are subject to risks and uncertainties. Wave Bye’s product is investigational and has not been evaluated or approved by the U.S. Food and Drug Administration.
Periods are a productivity and macroeconomic problem, not just a personal one.
Roughly 450 cycles in a lifetime, ~90% reporting pain, and an estimated $100 billion a year in lost productivity.
A $15B annual U.S. category nobody has treated as worth solving.
~450
cycles · ~7 years of bleeding
~90%
of women have pain or symptoms
~6
days of absenteeism per year
~23
days of reduced-capacity work per year
This shelf hasn’t changed since 1911.
Every box on the pain aisle says the same thing: take it when it hurts. The packaging changes. The instruction never has.
That is the white space. Not a new molecule — a new moment.
Unique timing, formulation, and packaging.
A proactive regimen only works if people take it proactively — a calendar-style blister pack, the day-by-day format that made oral contraceptives so well-adhered.
Designed against the clinical evidence base
Proactive and premenstrual by design
Built for a differentiated FDA label
Behavior-driven packaging
The products we sell right now are already validating the thesis.
150+
customers
$100+
average order value
~$60
customer acquisition cost
First
wholesale account, with repeat orders
Customers report less pain, less bleeding, and better daily functioning. Strong consumer signal — not yet clinical evidence. Our clinical program is underway.
Built by a physician who spent a career on this problem.
Founder and CEO Margo Harrison, MD, MPH, FACOG — Yale, Columbia, Johns Hopkins; NIH-funded faculty at the University of Colorado.
Backed by an advisory bench across regulatory strategy, drug development, clinical operations, brand, and commercial.
Why this work matters, and where it’s headed.
A large, durable addressable market
A genuine clinical white space
A differentiated, protectable approach
An independent, evidence-led path to market
A physician-led founding team
A clear regulatory roadmap
If you’d like to learn more about Wave Bye — the company, the science, or the market — leave your email and we’ll send you an informational overview. This is not an offer of any security, and no securities are being offered.
Footnotes & disclaimers
- Sources — market and epidemiology figures (450 cycles, 90%, 6 days, 23 days, $100B, $15B) are cited to their published sources.
- Regulatory status — Wave Bye's product is investigational and has not been evaluated or approved by the U.S. Food and Drug Administration. No claim of safety or efficacy is made for any Wave Bye product.
- Research attribution — efficacy figures described refer to published clinical studies of the underlying mechanism and dosing schedule, not to studies of Wave Bye's product.
- Beta data — consumer feedback reflects self-reported responses from customers of the beta products currently available for sale.
- Forward-looking statements — statements about the regulatory pathway, market size, pipeline, and business trajectory are forward-looking and subject to significant risks and uncertainties; actual results may differ materially. Wave Bye undertakes no obligation to update them.
- No offer or solicitation — this page is for informational purposes only and does not constitute an offer to sell, or a solicitation of an offer to buy, any security. No securities are being offered.
- wavebye™ is a trademark of Wave Bye Inc.